News Releases

– Continued strong performance of core royalty assets – – Demonstrated growth strategy execution through two transactions valued at up to $185 million – – Quarterly distribution doubled to…

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today it will hold a conference call to discuss its 2021 third quarter financial results on Tuesday, November 9,…

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that a subsidiary of the Trust has entered into a credit agreement with a syndicate of banks regarding US$200…

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today the acceptance by the Toronto Stock Exchange (the “TSX”) of the Trust’s Notice of Intention to make a normal…

– Oracea® is the only branded oral prescription medication indicated for papulopustular rosacea – TORONTO, Sept. 30, 2021 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it will be conducting a conference call to discuss the Trust’s previously announced debt and royalty…

– Transaction to Fund Launch and Commercialization of Pacritinib in the United States This Year Pending FDA Approval, and Future Commercialization – SEATTLE and TORONTO, Aug. 25, 2021 /CNW/ -…

– Quarter highlighted by strong performance from existing pharmaceutical products portfolio – TORONTO, Aug. 5, 2021 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”)…

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today it will hold a conference call to discuss its 2021 second quarter financial results on Friday, August 6, 2021, at

DRI Healthcare Trust (TSX: DHT.U) (TSX: DHT.UN) (“DRI” or “the Trust”) today announced its results for the period ended March 31, 2021. The Trust’s first quarter 2021 financial statements and…